Patients in England will be among those who are first to benefit from Sanofi and Regeneron’s new cancer immunotherapy Libtayo, after NICE recommended funding for a form of skin cancer immed
NHS England is to prioritise cancer drugs that target tumours according to their genetic makeup rather than where they originate in the body, the organisation’s chief executive has said.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
